Inclusion Criteria:  meeting the diagnostic criteria for acute ischemic stroke; Patients with complete anterior circulation infarction (TACI), partial anterior circulation infarction (PACI), lacunar infarction (LACI) in OCSP classification; Patients within 72 hours after onset; NIHSS score ≥4 points and ≤17 points; The modified Rankin Scale (MRS) score was between 0 and 1, and the MRS score before inclusion was > 2; Aged between 40 and 80 (including 40 and 80); 7) Signing the Informed Consent.  Exclusion Criteria:  intracranial hemorrhagic disease indicated by head CT or MRI, or disease with bleeding tendency; Patients treated with vascular opening (such as thrombolysis, arterial thrombectomy, ultra-early thrombosis aspiration and stenting, etc.) after the onset of this disease; Cerebral embolism caused by brain tumor, brain injury, brain parasitic disease, metabolic disorder, rheumatic heart disease and coronary heart disease confirmed by examination; Patients with other diseases affecting limb mobility, such as claudication, osteoarthritis (active stage), rheumatoid arthritis (active stage), gouty arthritis and other limb mobility disorders that may affect neurological function examination; Patients with post-treatment systolic blood pressure ≥180 mmHg or fasting blood glucose concentration < 2.8mmol/L; patients with severe heart and lung diseases and chronic liver and kidney dysfunction, including 1.5 times of the upper normal limit of liver function ALT and AST > and 1.2 times of the upper normal limit of renal function serum creatinine (SCR) >); patients with complicated mental illness who are unable or unwilling to cooperate; People with known allergies to the drug and its components (including excipients such as ethanol) and allergic constitution; Any other patients considered by the investigator to be unsuitable for inclusion or to be affected by factors affecting study participation or completion; Patients enrolled in other clinical trials within 1 month.